Tributary Capital Management LLC Sells 1,000 Shares of Eli Lilly And Co (LLY)

Tributary Capital Management LLC reduced its holdings in Eli Lilly And Co (NYSE:LLY) by 13.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 6,500 shares of the company’s stock after selling 1,000 shares during the quarter. Tributary Capital Management LLC’s holdings in Eli Lilly And Co were worth $843,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Ronna Sue Cohen boosted its stake in shares of Eli Lilly And Co by 8,473.2% in the 1st quarter. Ronna Sue Cohen now owns 214,586 shares of the company’s stock valued at $215,000 after purchasing an additional 212,083 shares during the last quarter. Northpointe Capital LLC bought a new stake in shares of Eli Lilly And Co in the 1st quarter valued at $2,109,000. DORCHESTER WEALTH MANAGEMENT Co bought a new stake in shares of Eli Lilly And Co in the 1st quarter valued at $541,000. Cohen Klingenstein LLC boosted its stake in shares of Eli Lilly And Co by 114.2% in the 1st quarter. Cohen Klingenstein LLC now owns 202,600 shares of the company’s stock valued at $26,289,000 after purchasing an additional 108,000 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its stake in shares of Eli Lilly And Co by 11.1% in the 1st quarter. Meeder Asset Management Inc. now owns 51,483 shares of the company’s stock valued at $6,681,000 after purchasing an additional 5,128 shares during the last quarter. Hedge funds and other institutional investors own 79.58% of the company’s stock.

Several research analysts recently issued reports on LLY shares. Barclays reissued a “buy” rating and set a $130.00 target price on shares of Eli Lilly And Co in a research note on Sunday, January 20th. BMO Capital Markets increased their target price on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a research note on Monday, December 24th. They noted that the move was a valuation call. JPMorgan Chase & Co. started coverage on shares of Eli Lilly And Co in a research note on Tuesday, March 12th. They set an “overweight” rating and a $140.00 target price on the stock. Guggenheim lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price on the stock. in a research note on Thursday, April 11th. Finally, Zacks Investment Research raised shares of Eli Lilly And Co from a “sell” rating to a “hold” rating in a research note on Tuesday, March 19th. Ten research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $118.02.

Eli Lilly And Co stock opened at $115.20 on Friday. Eli Lilly And Co has a 1-year low of $77.09 and a 1-year high of $132.13. The firm has a market capitalization of $119.33 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 2.18 and a beta of 0.33. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same period last year, the business posted $1.14 earnings per share. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Equities research analysts predict that Eli Lilly And Co will post 5.66 EPS for the current year.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the transaction, the insider now directly owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The disclosure for this sale can be found here. Insiders sold 867,382 shares of company stock worth $109,265,182 over the last ninety days. Insiders own 0.11% of the company’s stock.

WARNING: “Tributary Capital Management LLC Sells 1,000 Shares of Eli Lilly And Co (LLY)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/tributary-capital-management-llc-sells-1000-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Conference Calls and Individual Investors

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.